We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Compared to Estimates, HCA (HCA) Q2 Earnings: A Look at Key Metrics
Read MoreHide Full Article
For the quarter ended June 2023, HCA Healthcare (HCA - Free Report) reported revenue of $15.86 billion, up 7% over the same period last year. EPS came in at $4.29, compared to $4.21 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $15.57 billion, representing a surprise of +1.84%. The company delivered an EPS surprise of +0.23%, with the consensus EPS estimate being $4.28.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how HCA performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Equivalent Admissions: 938.83 million compared to the 923.41 million average estimate based on four analysts.
Revenue per Equivalent Admission: $16,894 compared to the $16,778.50 average estimate based on four analysts.
Number of hospitals: 182 versus the three-analyst average estimate of 180.82.
Licensed Beds at End of Period: 49063 compared to the 49020.53 average estimate based on two analysts.
Admissions: 523 million versus the two-analyst average estimate of 521.18 million.
Same Facility - Equivalent Admissions: 928.24 thousand versus 914.62 thousand estimated by two analysts on average.
Number of freestanding outpatient surgery centers: 126 compared to the 126.21 average estimate based on two analysts.
Patient Days: 2558.56 Days compared to the 2559.49 Days average estimate based on two analysts.
Equivalent Patient Days: 4594.6 thousand versus 4531.68 thousand estimated by two analysts on average.
Same Facility - Revenue per Equivalent Admission: $16,780 versus $16,930.95 estimated by two analysts on average.
Shares of HCA have returned -5.8% over the past month versus the Zacks S&P 500 composite's +5.6% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Compared to Estimates, HCA (HCA) Q2 Earnings: A Look at Key Metrics
For the quarter ended June 2023, HCA Healthcare (HCA - Free Report) reported revenue of $15.86 billion, up 7% over the same period last year. EPS came in at $4.29, compared to $4.21 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $15.57 billion, representing a surprise of +1.84%. The company delivered an EPS surprise of +0.23%, with the consensus EPS estimate being $4.28.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how HCA performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Equivalent Admissions: 938.83 million compared to the 923.41 million average estimate based on four analysts.
- Revenue per Equivalent Admission: $16,894 compared to the $16,778.50 average estimate based on four analysts.
- Number of hospitals: 182 versus the three-analyst average estimate of 180.82.
- Licensed Beds at End of Period: 49063 compared to the 49020.53 average estimate based on two analysts.
- Admissions: 523 million versus the two-analyst average estimate of 521.18 million.
- Same Facility - Equivalent Admissions: 928.24 thousand versus 914.62 thousand estimated by two analysts on average.
- Number of freestanding outpatient surgery centers: 126 compared to the 126.21 average estimate based on two analysts.
- Patient Days: 2558.56 Days compared to the 2559.49 Days average estimate based on two analysts.
- Equivalent Patient Days: 4594.6 thousand versus 4531.68 thousand estimated by two analysts on average.
- Same Facility - Revenue per Equivalent Admission: $16,780 versus $16,930.95 estimated by two analysts on average.
View all Key Company Metrics for HCA here>>>Shares of HCA have returned -5.8% over the past month versus the Zacks S&P 500 composite's +5.6% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.